Fig. 3

HXP protects against verapamil-induced zebrafish HF in a dose-dependent manner A. Zebrafish embryos at 48 hpf were pretreated with low, medium or high doses of HXP for 4 h followed by exposure to 100 μM verapamil for 30 min. Representative pictures of zebrafish embryos in each group are shown. The yellow and red-dotted lines indicate the area of the pericardial sac and venous congestion, respectively, scale bar = 200 μm. B. The phenotypes of embryos were classified as normal, moderate and severe according to the area of the pericardial sac and venous congestion, and the phenotypic proportions of zebrafish embryos in each group were statistically analyzed, n = 30. The experiment was replicated three times. C. Statistics of venous congestion area of zebrafish embryos in each group, n = 10. D. Statistics of the pericardial sac area of zebrafish embryos in each group, n = 11. E. Representative pictures of zebrafish heart morphology in each group, noting that the heart was dilated in the verapamil group and that the malformation of the heart could be rescued by different doses of HXP. F. Statistics of the area difference of ventricular diastole and systole of zebrafish embryos in each group, n = 10. G. Statistics of the heart rate of zebrafish embryos in each group, n = 30. H. Statistics of the ejection fraction of zebrafish hearts in each group, n = 11. I. Statistics of fraction shortening of zebrafish hearts in each group, n = 7; J. Statistics of cardiac stroke volume of zebrafish embryos in each group, n = 11. #, ### Compared with the control group (DMSO group); *, **, *** compared with the verapamil group.